HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Says Added Food Ingredients May Exceed GRAS Parameters

This article was originally published in The Tan Sheet

Executive Summary

An FDA guidance says some ingredients used at high levels in food products are generally recognized as safe for their intended, traditional use. But the trend of increasing the density of ingredients “raises questions as to whether these higher levels and other new conditions of use are safe.”

You may also be interested in...



Bioactive Ingredients: Maybe Difficult To Isolate, But US Regulatory Questions Are Obvious

FDA becoming increasingly strict in regulating bioactive, or functional ingredients in food and supplements. Planning ahead and incorporating R&D into regulatory compliance key to quicker approval.

Senate Bill Would Categorize Food Ingredients As Old And OK, Or New And Needing Approval

Bill would establish cutoff date for food ingredients to be made available as GRAS and not subject to food additive petition requirement. Also proposes establishing a FDA office for ongoing reviews of existing food additives and GRAS substances.

FDA Liquid Supplement/Beverage Guidance Defines Distinctions

The CFSAN guidance goes into greater detail on distinguishing liquid supplements from beverages, addressing stakeholders’ complaint about a 2009 draft. “This tends to really draw a bright line between the two different categories,” says CRN Regulatory Counsel Rend Al-Mondhiry.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139469

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel